HK Stock Market Move | KINTOR PHARMA-B (09939) rose by over 9%, cooperating with Founuo Medicine to develop KT-939 raw materials for whitening and spot-removing cosmetics.

KINTOR PHARMA-B (09939) rose by over 9%, up 7.27% to HK$4.28 as of the time of writing, with a trading volume of HK$145.832 million. In terms of news, Kintor Pharma announced that its wholly-owned subsidiary has signed a strategic cooperation agreement with Funuo Medicine to jointly develop innovative skincare products based on Kintor Pharma's innovative raw material KT-939, focusing on whitening and removing spots for improving skin pigmentation and treating melasma. The company plans to use the cash flow generated from the business of KT-939 skincare products to provide funding support for the development and commercialization of core products KX-826 and GT20029, as well as other pipeline products. It is worth noting that recently, Kintor Pharma stated on an investment platform that the Phase III clinical trial top-line data for its self-developed topical androgen receptor (AR) antagonist KX-826, a 1.0% lotion for the treatment of male androgenic alopecia (AGA), will be officially disclosed in late March 2026. With solid clinical data, KX-826 has successfully obtained the INCI designation for international cosmetic ingredients, becoming a compliant cosmetic raw material.